This is a demo store. No orders will be fulfilled.

Letolizumab (anti-TNFSF5) - Primary antibody, specific to CD40LG, VHH-Fc

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: VHH-Fc
  • Conjugation: Unconjugated
In stock
Item Number
Ab182769
Grouped product items
SKU Size
Availability
Price Qty
Ab182769-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
Ab182769-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$249.90
Ab182769-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$649.90
Ab182769-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,029.90

Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; VHH-Fc; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Letolizumab (anti-TNFSF5) - Primary antibody, specific to CD40LG, VHH-Fc
Synonyms CD154 antibody | CD40 antigen ligand antibody | CD40L antibody | CD40LG antibody | Gp39 antibody | HIGM1 antibody | Hyper IgM syndrome antibody | IGM antibody | IMD3 antibody | Ly62 antibody | T B cell activating molecule antibody | TBAM antibody | TNF re
Specifications & Purity Carrier Free, Recombinant, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity CD40LG
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, Low Endotoxin, Recombinant, Validated
Product Description

Letolizumab (anti-TNFSF5) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab (anti-TNFSF5) reduces rejection, thromboembolism and prolongs the survival time.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg

Product Properties

Isotype VHH-Fc
SDS-PAGE 26.3 kDa (Light Chain) & 53.0 kDa (Heavy Chain), under reducing conditions; 205.5 kDa, under non-reducing conditions.
Purification Method Protein A purified
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 1450981-87-9

Associated Targets(Human)

CD40LG Tbio CD40 ligand (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Letolizumab (anti-TNFSF5) (Ab182769) - Flow
Flow Cytometry analysis of pLVX-puro-SYMX10-TNFSF5(CD40L)-FL-HEK293 cells labelling TNFSF5 with Letolizumab (anti-TNFSF5) (Ab182769), and negative control protein respectively, washed and then followed by PE and analyzed with the FACS EC ₅₀  is 0.05 nM.

Letolizumab (anti-TNFSF5) (Ab182769) - ELISA
Immobilized Recombinant Human CD40 Ligand protein (rp169583) at 1.0 μg/mL can bind Letolizumab (anti-TNFSF5) (Ab182769) with the EC ₅₀   of 11.26 ng/mL.

Letolizumab (anti-TNFSF5) (Ab182769) - SEC
The purity of Letolizumab (anti-TNFSF5) (Ab182769) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0708870 Certificate of Analysis Jul 29, 2024 Ab182769
ZJ24F0708869 Certificate of Analysis Jul 29, 2024 Ab182769
ZJ24F0708868 Certificate of Analysis Jul 29, 2024 Ab182769

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.